तुलना करने के लिए मीट्रिक्स | 4891 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4891पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −8.1x | −9.0x | −0.5x | |
PEG अनुपात | −0.21 | −0.13 | 0.00 | |
क़ीमत/बुक | 2.0x | 2.8x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 18.7x | 3.0x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 137.3% | 58.7% | |
उचित मूल्य अपसाइड | अनलॉक करें | 10.0% | 10.3% | अनलॉक करें |
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. In addition, the company has a collaboration with Hokkaido University to evaluate the potential of the drug candidate compounds as novel drugs. TMS Co., Ltd. was incorporated in 2005 and is headquartered in Fuchu, Japan.